Survival estimates after pancreatoduodenectomy skewed by non-standardized histopathology reports

APMIS

Volumn 119, Issue 10, 2011, Pages 689-700

  Westgaard, Arne ^a,b   Clausen, Ole Petter F ^a,b   Gladhaug, Ivar P ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Long term survival; Pancreatic head adenocarcinoma; Standardized histopathological evaluation; Surgical resection; Tumour size

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; QUALITY CONTROL; SURVIVAL RATE; TISSUE SECTION;

ADENOCARCINOMA; AGED; AMPULLA OF VATER; BILE DUCT NEOPLASMS; COHORT STUDIES; COMMON BILE DUCT NEOPLASMS; DUODENAL NEOPLASMS; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NORWAY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 80052857737     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02783.x     Document Type: Article

References (56)

1. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology 2009;136:1134-44.
2. Soreide K, Aagnes B, Moller B, Westgaard A, Bray F. Epidemiology of pancreatic cancer in Norway: trends in incidence, basis of diagnosis and survival 1965-2007. Scand J Gastroenterol 2010;45:82-92.
3. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007;56:1134-52.
4. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry Gut 2005;54:385-7.
5. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg 2006;93:1232-7.
6. Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, et al. Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor. BMC Cancer 2008;8:5.
7. Westgaard A, Laronningen S, Mellem C, Eide TJ, Clausen OPF, Moller B, et al. Are survival predictions reliable? Hospital volume versus standardisation of histopathologic reporting for accuracy of survival estimates after pancreatoduodenectomy for adenocarcinoma. Eur J Cancer 2009;45:2850-9.
8. Sorg C, Schmidt J, Buchler MW, Edler L, Marten A. Examination of external validity in randomized controlled trials for adjuvant treatment of pancreatic adenocarcinoma. Pancreas 2009;38:542-50.
9. Wolff RA, Varadhachary GR, Evans DB. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol 2008;15:2773-86.
10. Katz MH, Merchant NB, Brower S, Branda M, Posner MC, William TL, et al. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol 2011;18:337-44.
11. Frierson HF Jr. The gross anatomy and histology of the gallbladder, extrahepatic bile ducts, Vaterian system, and minor papilla. Am J Surg Pathol 1989;13:146-62.
12. Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 2008;8:170.
13. Hruban RH, Pitman MB, Klimstra DS. Adenocarcinoma variants. In: Silverberg SG, Sobin LH editors. Tumors of the Pancreas. Fourth Series, Fascicle 6. In Series. AFIP Atlas of Tumor Pathology. Washington, DC: American Registry of Pathology, 2007: 165-90.
14. Albores-Saavedra J, Simpson K, Dancer YJ, Hruban R. Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann Diagn Pathol 2007;11:3-9.
15. Albores-Saavedra J, Henson DE, Klimstra DS. Malignant epithelial tumors of the ampulla. In: Rosai J, Sobin LH editors. Tumors of the Gallbladder, Extrahepatic Bile Ducts, and Ampulla of Vater. In Series. Atlas of tumor pathology, third series, fascicle 27. Washington, DC: Armed Forces Institute of Pathology, 2000: 259-316.
16. de Jong MC, Tsai S, Cameron JL, Wolfgang CL, Hirose K, van Vledder MG, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol 2010;102:256-63.
17. Westgaard A, Schjolberg AR, Cvancarova M, Eide TJ, Clausen OPF, Gladhaug IP. Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology 2009;54:337-47.
18. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 2008;247:456-62.
19. Adham M, Jaeck D, Le BJ, Oussoultzouglou E, Chenard-Neu MP, Mosnier JF, et al. Long-term survival (5-20years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas 2008;37:352-7.
20. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009;16:836-47.
21. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758-68.
22. Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004;40:549-58.
23. Jarufe NP, Coldham C, Mayer AD, Mirza DF, Buckels JA, Bramhall SR. Favourable prognostic factors in a large UK experience of adenocarcinoma of the head of the pancreas and periampullary region. Dig Surg 2004;21:202-9.
24. Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8:935-49.
25. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246:52-60.
26. Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford) 2009;11:18-24.
27. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer:a single-institution experience. J Gastrointest Surg 2006;10:1199-211.
28. Kazanjian KK, Hines OJ, Duffy JP, Yoon DY, Cortina G, Reber HA. Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg 2008;143:1166-71.
29. Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008;15:1651-60.
30. Smith RA, Bosonnet L, Ghaneh P, Raraty M, Sutton R, Campbell F, et al. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg 2008;25:226-32.
31. Kato K, Yamada S, Sugimoto H, Kanazumi N, Nomoto S, Takeda S, et al. Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: influence of resection margin status on survival. Pancreas 2009;38:605-12.
32. Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009;27:2855-62.
33. Bilimoria KY, Talamonti MS, Sener SF, Bilimoria MM, Stewart AK, Winchester DP, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 2008;207:510-9.
34. Verbeke CS. Resection margins and R1 rates in pancreatic cancer - Are we there yet? Histopathology 2008;52:787-96.
35. Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA. Peri-ampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998;227:821-31.
36. Katz MH, Bouvet M, Al Refaie W, Gilpin EA, Moossa AR. Non-pancreatic peri-ampullary adenocarcinomas: an explanation for favorable prognosis. Hepatogastroenterology 2004;51:842-6.
37. Schmidt CM, Powell ES, Yiannoutsos CT, Howard TJ, Wiebke EA, Wiesenauer CA, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 2004;139:718-27.
38. Kuhlmann K, de Castro S, van Heek T, Busch O, van Gulik T, Obertop H, et al. Microscopically incomplete resection offers acceptable palliation in pancreatic cancer. Surgery 2006;139:188-96.
39. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008;143:75-83.
40. Bandyopadhyay S, Basturk O, Coban I, Thirabanjasak D, Liang H, Altinel D, et al. Isolated solitary ducts (naked ducts) in adipose tissue: a specific but underappreciated finding of pancreatic adenocarcinoma and one of the potential reasons of understaging and high recurrence rate. Am J Surg Pathol 2009;33:425-9.
41. Hruban RH, Pitman MB, Klimstra DS. Classification of pancreatic tumors. In: Silverberg SG, Sobin LH editors. Tumors of the Pancreas. Fourth Series, Fascicle 6. In Series. AFIP Atlas of Tumor Pathology. Washington, DC: American Registry of Pathology, 2007: 111-64.
42. Campbell F, Foulis AK, Verbeke CS. Dataset for the histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct. Standards and datasets for reporting cancers, 2010. Available at: Accessed February 8, 2011.
43. Wittekind C, Compton C, Quirke P, Nagtegaal I, Merkel S, Hermanek P, et al. A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status. Cancer 2009;115:3483-8.
44. Kim J, Reber HA, Dry SM, Elashoff D, Chen SL, Umetani N, et al. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut 2006;55:1598-605.
45. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66:56-61.
46. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, et al. Long-term survival and metastatic pattern of pancreatic and peri-ampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007;246:734-40.
47. Kinsella TJ, Seo Y, Willis J, Stellato TA, Siegel CT, Harpp D, et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol 2008;31:446-53.
48. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004;70:235-40.
49. Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007;141:610-8.
50. Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008;15:165-74.
51. Hurtuk MG, Hughes C, Shoup M, Aranha GV. Does lymph node ratio impact survival in resected peri-ampullary malignancies? Am J Surg 2009;197:348-52.
52. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakashima A, et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg 2010;211:196-204.
53. Khalifa MA, Maksymov V, Rowsell C. Retroperitoneal margin of the pancreaticoduodenectomy specimen: anatomic mapping for the surgical pathologist. Virchows Arch 2009;454:125-31.
54. Henson DE, Schwartz AM, Nsouli H, Albores-Saavedra J. Carcinomas of the pancreas, gallbladder, extrahepatic bile ducts, and ampulla of vater share a field for carcinogenesis: a population-based study. Arch Pathol Lab Med 2009;133:67-71.
55. Sarmiento JM, Nagomey DM, Sarr MG, Farnell MB. Peri-ampullary cancers: are there differences? Surg Clin North Am 2001;81:543-55.
56. Kimura W, Futakawa N, Yamagata S, Wada Y, Kuroda A, Muto T, et al. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res 1994;85:161-6.